Effect of renal function on pemetrexed-induced haematotoxicity-Reference-Cited by-同舟云学术

Effect of renal function on pemetrexed-induced haematotoxicity

Published:2016-06-10 Issue:1 Volume:78 Page:183-189
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ando Yosuke,Hayashi Takahiro,Ujita Moeko,Murai Sumie,Ohta Hideki,Ito Kaori,Yamaguchi Teppei,Funatsu Minori,Ikeda Yoshiaki,Imaizumi Kazuyoshi,Kawada Kenji,Yasuda Kimio,Yamada Shigeki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-016-3078-7.pdf

Reference34 articles.

1. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128. doi: 10.1016/S1470-2045(09)70364-X

2. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246. doi: 10.1016/S1470-2045(11)70393-X

3. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742. doi: 10.1016/S1470-2045(11)70184-X

4. Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222. doi: 10.1016/S1470-2045(13)70604-1

5. Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study;2024-08-09

2. Cancer drugs and acute kidney injury: new therapies and new challenges;Current Opinion in Nephrology & Hypertension;2024-05-07

3. Disease control in patients with non‐small cell lung cancer using pemetrexed: Investigating the best treatment strategy;Thoracic Cancer;2024-03-14

4. Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer;Cancer Medicine;2023-06-23

5. Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial;Cancer Chemotherapy and Pharmacology;2022-11-21